Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis

References

• BuchbinderEIDesaiACTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibitionAm J Clin Oncol20163919810626558876
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimD-WPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
   PubMed Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet2016387100311909192026952546
   PubMed Web of Science ®Google Scholar
• DowneySGKlapperJASmithFOPrognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockadeClin Cancer Res20071322 pt 16681668817982122
   PubMed Web of Science ®Google Scholar
• BronsteinYNgCSHwuPRadiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti–CTLA-4 antibody therapyAm J Roentgenol20111976W992W100022109345
   PubMed Web of Science ®Google Scholar
• GettingerSNHornLGandhiLOverall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancerJ Clin Oncol201533182004201225897158
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non–small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti–PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
   PubMed Web of Science ®Google Scholar
• WeberJSDummerRde PrilVPatterns of onset and resolution of immune-related adverse events of special interest with ipilimumabCancer201311991675168223400564
   PubMed Web of Science ®Google Scholar
• RizviNAMazièresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol201516325726525704439
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• CostaRCarneiroBAAgulnikMToxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsOncotarget2017858910892027852042
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• NishinoMGiobbie-HurderAHatabuHIncidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysisJAMA Oncol20162121607161627540850
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• NaidooJWangXWooKMPneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapyJ Clin Oncol201735770971727646942
   PubMed Web of Science ®Google Scholar
• BarjaktarevicIZQadirNSuriASantamauroJTStoverDOrganizing pneumonia as a side effect of ipilimumab treatment of melanomaChest2013143385886123460165
   PubMed Web of Science ®Google Scholar
• TirumaniSHRamaiyaNHKeraliyaARadiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumabCancer Immunol Res20153101185119226100356
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (Anti–PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
   PubMed Web of Science ®Google Scholar
• NagataSUedaNYoshidaYMatsudaHMaeharaYSevere interstitial pneumonitis associated with the administration of taxanesJ Infect Chemother201016534034420354889
   PubMed Web of Science ®Google Scholar
• MasahikoAIsamuONobuyukiYPredictive factors for interstitial lung disease, antitumor response, and survival in non–small-cell lung cancer patients treated with gefitinibJ Clin Oncol200624162549255616735708
   PubMed Web of Science ®Google Scholar
• TakanoTOheYKusumotoMRisk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinibLung Cancer20044519310415196739
   PubMed Web of Science ®Google Scholar
• GuptaNAhmedISteinbergHGemcitabine-induced pulmonary toxicity: case report and review of the literatureAm J Clin Oncol20022519610011823707
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• McDermottDFSosmanJASznolMAtezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia studyJ Clin Oncol201634883384226755520
   PubMed Web of Science ®Google Scholar
• KuboKAzumaAKanazawaMConsensus statement for the diagnosis and treatment of drug-induced lung injuriesRespir Investig2013514260277
   PubMedGoogle Scholar
• NishinoMRamaiyaNHAwadMMPD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical courseClin Cancer Res201622246051606027535979
   PubMed Web of Science ®Google Scholar
• NishinoMShollLMHatabuHAnti–PD-1–related pneumonitis during cancer immunotherapyN Engl J Med2015373328829026176400
   PubMed Web of Science ®Google Scholar
• FriedmanCFProverbs-SinghTAPostowMATreatment of the immune-related adverse effects of immune checkpoint inhibitors: a reviewJAMA Oncol20162101346135327367787
   PubMed Web of Science ®Google Scholar
• MisLClarkeJMIpilimumab-induced pneumonitis: a case reportJ Pharm Technol2013299498
   Google Scholar
• KollaBCPatelMRRecurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy– a report of two casesJ Immunother Cancer201648027895919
   PubMed Web of Science ®Google Scholar
• BerthodGLazorRLetovanecIPulmonary sarcoid-like granulo-matosis induced by ipilimumabJ Clin Oncol20123017e156e15922547608
   PubMed Web of Science ®Google Scholar
• BasheyAMedinaBCorringhamSCTLA4 blockade with ipi-limumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationBlood200911371581158818974373
   PubMed Web of Science ®Google Scholar
• MontaudiéHPradelliJPasseronTLacourJPLeroySPulmonary sarcoid-like granulomatosis induced by nivolumabBr J Dermatol201717641060106327291635
   PubMed Web of Science ®Google Scholar
• DanlosF-XPagèsCBaroudjianBNivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanomaChest20161495e133e13627157227
   PubMed Web of Science ®Google Scholar
• KoelzerVHRothschildSIZihlerDSystemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy studyJ Immunother Cancer201641326981243
   PubMed Web of Science ®Google Scholar
• GarreanSMassadMGTshibakaMHanhanZCainesAEBenedettiESirolimus-associated interstitial pneumonitis in solid organ transplant recipientsClin Transplant200519569870316146565
   PubMed Web of Science ®Google Scholar
• MohyuddinGRSultanFZhangKKhaleeqGSulfasalazine induced lung toxicity masquerading as sarcoidosis – case report and review of the literatureSarcoidosis Vasc Diffuse Lung Dis201330322623024284297
   PubMed Web of Science ®Google Scholar
• TroyZHNellyGAThu-OanhDImmune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer CenterJ Clin Oncol201533283193319826282644
   PubMed Web of Science ®Google Scholar
• WeberJSAntoniaSJTopalianSLSafety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysisASCO Annu Meet Proc2015339018
   Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar